Insulin-like growth factor 1 receptor and response to anti-IGF1R antibody therapy in osteosarcoma

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Cao, Yu ^a   Roth, Michael ^a   Piperdi, Sajida ^a   Montoya, Kristofer ^a   Sowers, Rebecca ^a   Rao, Pulivarthi ^b   Geller, David ^a   Houghton, Peter ^c   Kolb, E Anders ^d   Gill, Jonathan ^a   Gorlick, Richard ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c NATIONWIDE CHILDREN S HOSPITAL   (United States)

^d NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [4 [(5 CYCLOPROPYL 1H PYRAZOL 3 YL)AMINO]PYRROLO[2,1 F][1,2,4]TRIAZIN 2 YL] N (6 FLUORO 3 PYRIDINYL) 2 METHYL 2 PYRROLIDINECARBOXAMIDE; CIXUTUMUMAB; MESSENGER RNA; ROBATUMUMAB; SOMATOMEDIN C RECEPTOR; ANTINEOPLASTIC AGENT; CANCER ANTIBODY; RNA; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG RESPONSE; EXON; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DOSAGE; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; INSULIN LIKE GROWTH FACTOR 1 RECEPTOR GENE; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; OSTEOSARCOMA; PRIMARY TUMOR; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; DRUG EFFECTS; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; MALE; METABOLISM; PATHOLOGY; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, SCID; NEOPLASM PROTEINS; OSTEOSARCOMA; RECEPTOR, IGF TYPE 1; RNA, MESSENGER; RNA, NEOPLASM; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84919468696     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0106249     Document Type: Article

References (46)

1. Chou AJ, Geller DS, Gorlick R (2008) Therapy for osteosarcoma: where do we go from here? Paediatr Drugs 10: 315-327.
2. O'Day K, Gorlick R (2009) Novel therapeutic agents for osteosarcoma. Expert Rev Anticancer Ther 9: 511-523.
3. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, et al. (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348: 994-1004. (Pubitemid 36302244)
4. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, et al. (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. New England Journal of Medicine 353: 1659-1672. (Pubitemid 41464705)
5. Perez EA, Baweja M (2008) HER2-positive breast cancer: current treatment strategies. Cancer Invest 26: 545-552. (Pubitemid 351918580)
6. Pollak MN, Schernhammer ES, Hankinson SE (2004) Insulin-like growth factors and neoplasia. Nat Rev Cancer 4: 505-518. (Pubitemid 38868620)
7. Burrow S, Andrulis IL, Pollak M, Bell RS (1998) Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma. J Surg Oncol 69: 21-27. (Pubitemid 28452269)
8. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, et al. (1998) Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279: 563-566. (Pubitemid 28067285)
9. Chan JM, Stampfer MJ, Ma J, Gann P, Gaziano JM, et al. (2002) Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 94: 1099-1106. (Pubitemid 34830730)
10. Diorio C, Pollak M, Byrne C, Masse B, Hebert-Croteau N, et al. (2005) Insulin-like growth factor-I, IGF-binding protein-3, and mammographic breast density. Cancer Epidemiol Biomarkers Prev 14: 1065-1073. (Pubitemid 40656449)
11. Giovannucci E, Pollak MN, Platz EA, Willett WC, Stampfer MJ, et al. (2000) A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomarkers Prev 9: 345-349. (Pubitemid 30265776)
12. Hankinson SE, Schernhammer ES (2003) Insulin-like growth factor and breast cancer risk: evidence from observational studies. Breast Dis 17: 27-40. (Pubitemid 38180806)
13. Palmqvist R, Hallmans G, Rinaldi S, Biessy C, Stenling R, et al. (2002) Plasma insulin-like growth factor 1, insulin-like growth factor binding protein 3, and risk of colorectal cancer: a prospective study in northern Sweden. Gut 50: 642-646. (Pubitemid 34407490)
14. Cao L, Yu Y, Darko I, Currier D, Mayeenuddin LH, et al. (2008) Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. Cancer research 68: 8039-8048.
15. Pollak M (2008) Insulin, insulin-like growth factors and neoplasia. Best Pract Res Clin Endocrinol Metab 22: 625-638.
16. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE (2000) The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 21: 215-244. (Pubitemid 32275588)
17. Gooch JL, Van Den Berg CL, Yee D (1999) Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death - proliferative and anti-apoptotic effects. Breast Cancer Res Treat 56: 1-10. (Pubitemid 29435810)
18. Kolb EA, Gorlick R (2009) Development of IGF-IR Inhibitors in Pediatric Sarcomas. Curr Oncol Rep 11: 307-313.
19. Kolb EA, Gorlick R, Houghton PJ, Morton CL, Lock R, et al. (2008) Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer 50: 1190-1197. (Pubitemid 351555543)
20. Yuen JS, Macaulay VM (2008) Targeting the type 1 insulin-like growth factor receptor as a treatment for cancer. Expert Opin Ther Targets 12: 589-603. (Pubitemid 351699478)
21. Houghton PJ, Morton CL, Gorlick R, Kolb EA, Keir ST, et al. (2010) Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the pediatric preclinical testing program. Pediatric blood & cancer 54: 921-926.
22. Kolb EA, Gorlick R, Lock R, Carol H, Morton CL, et al. (2011) Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program. Pediatric blood & cancer 56: 595-603.
23. Tognon CE, Sorensen PH (2012) Targeting the insulin-like growth factor 1 receptor (IGF1R) signaling pathway for cancer therapy. Expert opinion on therapeutic targets 16: 33-48.
24. Gao J, Chang YS, Jallal B, Viner J (2012) Targeting the insulin-like growth factor axis for the development of novel therapeutics in oncology. Cancer Research 72: 3-12.
25. Asmane I, Watkin E, Alberti L, Duc A, Marec-Berard P, et al. (2012) Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas. Eur J Cancer 48: 3027-3035.
26. Bagatell R, Herzog CE, Trippett TM, Grippo JF, Cirrincione-Dall G, et al. (2011) Pharmacokinetically guided phase 1 trial of the IGF-1 receptor antagonist RG1507 in children with recurrent or refractory solid tumors. Clin Cancer Res 17: 611-619.
27. Juergens H, Daw NC, Geoerger B, Ferrari S, Villarroel M, et al. (2011) Preliminary Efficacy of the Anti-Insulin - Like Growth Factor Type 1 Receptor Antibody Figitumumab in Patients With Refractory Ewing Sarcoma. Journal of Clinical Oncology 29: 4534-4540.
28. Anderson P SK, Miller R, Meyer W, Lu B (2008) Activity of SCH 717454 in subjects with relapsed osteosarcoma or Ewing's sarcoma (study P04720). In: Proceedings of the 14th Annual Meeting of the Connective Tissue Oncology Society (CTOS '08) London, UK. abstract no. 35094.
29. Wan X, Harkavy B, Shen N, Grohar P, Helman L (2006) Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 26: 1932-1940.
30. Kurmasheva RT, Dudkin L, Billups C, Debelenko LV, Morton CL, et al. (2009) The Insulin-like Growth Factor-1 Receptor - Targeting Antibody, CP-751,871, Suppresses Tumor-Derived VEGF and Synergizes with Rapamycin in Models of Childhood Sarcoma. Cancer Research 69: 7662-7671.
31. Schwartz GK, Tap WD, Qin L-X, Livingston MB, Undevia SD, et al. (2013) Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. The lancet oncology.
32. Quek R, Wang Q, Morgan JA, Shapiro GI, Butrynski JE, et al. (2011) Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin Cancer Res 17: 871-879.
33. Tolcher AW, Sarantopoulos J, Patnaik A, Papadopoulos K, Lin C-C, et al. (2009) Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol 27: 5800-5807.
34. Reidy DL, Vakiani E, Fakih MG, Saif MW, Hecht JR, et al. (2010) Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab-or panitumumab-refractory metastatic colorectal cancer. J Clin Oncol 28: 4240-4246.
35. Schmitz S, Kaminsky-Forrett M-C, Henry S, Zanetta S, Geoffrois L, et al. (2012) Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: clinical activity and molecular response (GORTEC 2008-02). Ann Oncol 23: 2153-2161.
36. Olmos D, Postel-Vinay S, Molife L, Okuno SH, Schuetze SM, et al. (2010) Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. The lancet oncology 11: 129-135.
37. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, et al. (2010) Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. New England Journal of Medicine 362: 2260-2270.
38. Kindler H, Richards D, Garbo L, Garon E, Stephenson J, et al. (2012) A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. Ann Oncol 23: 2834-2842.
39. Davis AM, Bell RS, Goodwin PJ (1994) Prognostic factors in osteosarcoma: a critical review. J Clin Oncol 12: 423-431. (Pubitemid 24056419)
40. Zha J, O'Brien C, Savage H, Huw L-Y, Zhong F, et al. (2009) Molecular predictors of response to a humanized anti - insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer. Molecular cancer therapeutics 8: 2110-2121.
41. Fleuren ED, Versleijen-Jonkers YM, van de Luijtgaarden AC, Molkenboer-Kuenen JD, Heskamp S, et al. (2011) Predicting IGF-1R therapy response in bone sarcomas: immuno-SPECT imaging with radiolabeled R1507. Clinical Cancer Research 17: 7693-7703.
42. Zha J, Lackner MR (2010) Targeting the insulin-like growth factor receptor-1R pathway for cancer therapy. Clin Cancer Res 16: 2512-2517.
43. Avnet S, Sciacca L, Salerno M, Gancitano G, Cassarino MF, et al. (2009) Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma. Cancer research 69: 2443-2452.
44. Pandini G, Vigneri R, Costantino A, Frasca F, Ippolito A, et al. (1999) Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling. Clinical Cancer Research 5: 1935-1944. (Pubitemid 29334478)
45. Voskoglou-Nomikos T, Pater JL, Seymour L (2003) Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res 9: 4227-4239. (Pubitemid 37204044)
46. Arcaro A (2013) Targeting the insulin-like growth factor-1 receptor in human cancer. Frontiers in pharmacology 4.